Financial Performance - Total revenue for 2025 was CNY 340.38 million, a decrease of 2.64% compared to the previous year[4] - Net profit attributable to shareholders of the parent company was a loss of CNY 39.71 million, an increase in loss of CNY 37.71 million year-on-year[9] - The net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was a loss of CNY 103.83 million, an increase in loss of CNY 31.99 million year-on-year[9] - Basic earnings per share were CNY -0.47, compared to CNY -0.02 in the previous year[5] Assets and Equity - Total assets at the end of the reporting period were CNY 3,553.83 million, a decrease of 4.98% from the beginning of the period[9] - Shareholders' equity attributable to the parent company was CNY 2,929.90 million, a decrease of 9.87% from the beginning of the period[9] Operational Insights - The company’s gross profit margin is expected to remain stable compared to the previous year despite industry competition and VAT adjustments[9] - The company has focused on R&D, maintaining a relatively high intensity of investment in product development[11] - The company has faced a reduction in government subsidies received during the reporting period[10] Shareholder Changes - The number of shares increased by 48% due to a capital reserve conversion plan implemented in June 2025[11]
硕世生物(688399) - 2025 Q4 - 年度业绩